GlassScriptPhysician profile
Katherine Grasso
NPI 1184093106
$4,828.79
in general payments reported to CMS, 2019-2025
28 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $540 · 2023: $877 · 2024: $1,344 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,828 · Education: $15.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,828.27 |
| Education | $15.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,446.08 | 2021-2025 | |
| Janssen Biotech, INC. | $522.80 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $415.53 | 2021-2025 | Entyvio |
| Gilead Sciences, INC. | $331.97 | 2022-2025 | Livdelzi, Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.70 | 2021-2025 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $316.23 | 2021-2024 | Tremfya, Stelara |
| Genzyme Corporation | $277.23 | 2022-2025 | |
| Celgene Corporation | $183.27 | 2021-2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $153.60 | 2025 | Terlivaz |
| Pfizer INC. | $149.16 | 2022-2025 | |
| Ardelyx, INC. | $125.87 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $103.85 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $75.85 | 2023-2025 | Dupixent |
| Daiichi Sankyo INC. | $68.15 | 2021-2024 | Injectafer |
| Qol Medical, LLC | $66.45 | 2021-2025 | Sucraid, Sucraid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57.61 | 2024-2025 | Omvoh |
| Stryker Corporation | $41.75 | 2024 | Mako |
| Phathom Pharmaceuticals, INC. | $19.03 | 2025 | Voquezna |
| Novo Nordisk INC | $18.52 | 2025 | Wegovy |
| Evoke Pharma, INC. | $17.67 | 2021 | |
| Celltrion USA INC. | $15.01 | 2024 | Zymfentra |
| Intercept Pharmaceuticals, INC. | $14.98 | 2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $14.73 | 2022 | |
| Aimmune Therapeutics, INC. | $14.57 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $14.36 | 2025 | Iqirvo |
| Ethicon US, LLC | $14.31 | 2023 | Surgicel Nu-Knit |
| Teleflex LLC | $13.20 | 2024 | Solesta |
| Redhill Biopharma INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Grasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.